ReviewCurrent treatment options in neurology2018
Anti-IgLON 5 Disease.
Review in Current treatment options in neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Anti-IgLON5 Disease: A Systematic Review and Meta-Analysis.European journal of neurology · 2025Pooled it
- Epileptic Seizures and Right-Sided Hippocampal Swelling as Presenting Symptoms of Anti-IgLON5 Disease: A Case Report and Systematic Review of the Literature.Frontiers in neurology · 2022Pooled it
- Genotype-Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review.Movement disorders : official journal of the Movement Disorder Society · 2021Pooled it
- From Normal Variation in Sleep to Clinical Sleep Disorders: Genetic Insights from Over One Million Individuals.medRxiv : the preprint server for health sciences · 2025Article
- Causes of Death in Anti-IgLON5 Disease: A Novel Case Report and Systematic Literature Review.Brain sciences · 2025Article
- Acute onset of anti-IgLON5 disease with meningeal enhancement: a case report.BMC neurology · 2025Article
- Clinical analysis and literature review of two paediatric cases of anti-IgLON5 antibody-related encephalitis.Frontiers in neurology · 2024Article
- The psychiatric symptoms in anti-IgLON5 disease: Case report and literature review.Clinical case reports · 2024Article
- Atypical neurological manifestations in anti-IgLON5 disease: a case report.Frontiers in neurology · 2024Article
- [The anti-IgLON5 syndrome in clinical neurology-Report of two cases].Der Nervenarzt · 2022Article
- Bilateral horizontal gaze palsy due to Anti-IgLON5 disease.American journal of ophthalmology case reports · 2022Article
- Rapidly progressive dementia: Extending the spectrum of GFAP-astrocytopathies?Annals of clinical and translational neurology · 2022Article
- Sleep medicine: Practice, challenges and new frontiers.Frontiers in neurology · 2022Review
- Anti-IgLON5 Disease - The Current State of Knowledge and Further Perspectives.Frontiers in immunology · 2022Review
- Musical hallucinations: a rare and atypical presentation of anti-IgLON5 disease responsive to immunosuppressive therapy.BMJ case reports · 2021Article
- Sleep Disturbances in Autoimmune Neurologic Diseases: Manifestation and Pathophysiology.Frontiers in neuroscience · 2021Review
- Unusual Head Movements in Anti-IgLON5 Disease.Movement disorders clinical practice · 2020Article
- Education Research: Multiple sclerosis and neuroimmunology fellowship training status in the United States.Neurology · 2020Article
- Sleep and neurological autoimmune diseases.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Review
- Intersection of pathological tau and microglia at the synapse.Acta neuropathologica communications · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review aims to give an overview about the current knowledge of this novel neurological disorder associated to IgLON-5 antibodies and its treatment. RECENT
findingsAnti-IgLON5 disease was first formally described in 2014. This newly discovered disorder recaps a complex neurological disorder with sleep, movement, and neuroimmunological and neurodegenerative aspects. The clinical manifestation of the anti-IgLON5 disease is very heterogeneous mostly including a sleep disorder with non-rapid eye movement (REM) sleep parasomnia and REM behavior disorder besides obstructive sleep apnea syndrome and stridor. Other neurological features (bulbar symptoms, gait abnormalities, cognitive dysfunction) are common. Until today, the mean age of diagnosis was mostly above the age of 60 with a balanced distribution of sex. Neuropathological examination showed neuronal loss and gliosis associated with an atypical tauopathy mainly involving the tegmentum of brainstem and hypothalamus. Although the function of the antibodies stays unclear so far, the evidence for the pathogenetic role of the antibody becomes more evident. Among the association to HLA-DRB1*10:01 and HLA-DQB1*05:01 as a potential factor for susceptibility, immunopathological findings are promising. So far, the pathophysiology of anti-IgLON5 disease is not sufficiently enlightened and needs more interdisciplinary approach to a better understanding of this interesting disorder at the border of autoimmunity and neurodegeneration. Immunotherapy has been frequently used but its therapeutic effect is limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.